DrugPatentWatch Database Preview
TRITEC Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Tritec patents expire, and what generic alternatives are available?
Tritec is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in TRITEC is ranitidine bismuth citrate. There are forty-three drug master file entries for this compound. Additional details are available on the ranitidine bismuth citrate profile page.
Summary for TRITEC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for TRITEC |
| DailyMed Link: | TRITEC at DailyMed |
Recent Litigation for TRITEC
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| In re: &039318 Patent Infringement Litigation | 2005-06-03 |
| In re: '318 Patent Infringement Litigation | 2005-06-03 |
US Patents and Regulatory Information for TRITEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | DISCN | No | No | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRITEC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | Start Trial | Start Trial |
| Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | Start Trial | Start Trial |
| Glaxosmithkline | TRITEC | ranitidine bismuth citrate | TABLET;ORAL | 020559-001 | Aug 8, 1996 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRITEC
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 244390 | Start Trial |
| Denmark | 351789 | Start Trial |
| Hungary | 206104 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
